The effects of transient cerebral ischemia on vasopressin-induced vasoconstriction in rabbit cerebral vessels.
BACKGROUND
Vasopressin is a drug of choice for use during cardiopulmonary resuscitation because several experimental studies have shown that it is better than epinephrine at increasing systemic perfusion pressure and improving cerebral perfusion pressure without increasing myocardial oxygen consumption. We used a pial window preparation to determine the effects of vasopressin when applied topically to pial vessels and whether any effects were altered after cerebral ischemia in rabbits (n = 27).


METHODS
We first examined the effects of topical application of arginine-vasopressin (AVP) (10(-11) M, 10(-9) M, 10(-7) M, and 10(-5) M, sequentially). We then examined the effects of topical application of AVP (10(-9) M and 10(-7) M, sequentially) before and after a 5-min intervention consisting of cerebral ischemia produced by inflation of a neck tourniquet plus systemic hypotension or systemic hypotension alone.


RESULTS
Pial arteriolar diameters were (a) dilated by 10(-11) M AVP [7% +/- 11% (P = 0.014 versus baseline)], but constricted by 10(-9) M, 10(-7) M, and 10(-5) M AVP [7% +/- 14%, 20% +/- 14%, and 16% +/- 16% (each P < 0.05), respectively], and (b) constricted before hypotension (7% +/- 10% at 10(-9) M, 20% +/- 15% at 10(-7) M) or ischemia (7% +/- 11% at 10(-9) M, 21% +/- 15% at 10(-7) M). However, after the 5-min of ischemia, the decrease in diameter induced by 10(-7) M AVP was significantly reduced but not by hypotension alone [hypotension control group: 7% +/- 10% at 10(-9) M, 19% +/- 14% at 10(-7) M; ischemia group: 5% +/- 11% at 10(-9) M, 10% +/- 13% at 10(-7) M (P = 0.35 versus hypotension control)].


CONCLUSIONS
Topical application of AVP (except at the lowest concentration used here) induced concentration-dependent vasoconstriction of pial arterioles in anesthetized rabbits. The vasoconstrictor effect of 10(-7) M AVP was reduced after transient (5-min) cerebral ischemia.
Kumazawa
Masahiko
M
Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu City, Gifu 501-1194, Japan.
Iida
Hiroki
H
Uchida
Masayoshi
M
Iida
Mami
M
Takenaka
Motoyasu
M
Fukuoka
Naokazu
N
Michino
Tomohiro
T
Dohi
Shuji
S
D000287:Administration, Topical; D000818:Animals; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000378:metabolism*; D001160:Arterioles / Q000378:metabolism / Q000503:physiopathology; D002545:Brain Ischemia / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006439:Hemodynamics; D007022:Hypotension / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D010841:Pia Mater / Q000098:blood supply*; D011817:Rabbits; D014111:Tourniquets; D014661:Vasoconstriction; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000378:metabolism*
D014662:Vasoconstrictor Agents; D001127:Arginine Vasopressin